Trial Profile
An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 17 Jan 2019 Planned End Date changed from 30 Oct 2019 to 30 Jun 2029.
- 17 Jan 2019 Planned primary completion date changed from 30 Oct 2019 to 30 Jun 2029.
- 30 Oct 2018 Planned End Date changed from 30 Sep 2019 to 30 Oct 2019.